Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients

Date

14 Sep 2024

Session

Poster session 10

Topics

Patient Education and Advocacy;  Supportive and Palliative Care;  Survivorship

Tumour Site

Small Cell Lung Cancer;  Non-Small Cell Lung Cancer

Presenters

Shani Shilo

Citation

Annals of Oncology (2024) 35 (suppl_2): S913-S922. 10.1016/annonc/annonc1604

Authors

S. Shilo1, H. Silman2, D. Urban3, A. Zer4, A. Bar-Shai5, S. Epstein6, A. Agbarya7, N. Peled8

Author affiliations

  • 1 Ceo, The Israeli Lung Cancer Foundation, 7608654 - Rehovot/IL
  • 2 Oncology, Rambam Hospital, 3109601 - Haifa/IL
  • 3 Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 4 Medical Oncology Department, Rambam Health Care Campus, 3109601 - Haifa/IL
  • 5 Pulmonology, Ichilov Medical center, 6423906 - Tel Aviv/IL
  • 6 Projects, The Israeli Lung Cancer Foundation, 7608654 - Rehovot/IL
  • 7 Oncology, Bnai Zion Medical Center, 31048 - Haifa/IL
  • 8 Cancer Center, Shaare Zedek Medical Center, 9103102 - Jerusalem/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1486P

Background

Living with lung cancer (LC) becomes a long journey where disease consequences and treatment adverse events impact quality of life (QOL) of the patient and the caregiver. Here, HCP's and a patient organization developed and executed a personalized respiratory and physical rehabilitation pilot program for unresectable metastatic LC patients.

Methods

25 stage IV unresectable patients were recruited from a Facebook post. They received 4 physiotherapist visits, where a personalized physiotherapy program was tailored, using a personal booklet and equipment provision. All received two types of recommendations: aerobic and strength activities. The patients and caregivers also received 3 online mental support sessions. EORTC QLQ-C30 questionnaire was used at the beginning, end of the program and two months after. The physiotherapists measured the patients’ 5 repetitions sit to stand time and 10-meter walk time at the beginning and the end of the program. Significance of results was calculated with repeated measurewithin subjects T test with one way hypothesis and a confident interval of 0.95%.

Results

Significant and maintained improvement was observed in the Sit-to-stand test, from 14.9s to 12.8s, p=0.012, the 10-meter-walk test, from 0.89m/s to 1.22m/s, p=0.014, the global health status and constipation p<0.05. In addition, emotional and social functioning, fatigue symptoms and appetite loss were improved after the intervention, whereas weren't maintained two months after completion of the program. No significant change was observed in cognitive functioning, pain symptoms, dyspnea, insomnia, diarrhea and financial difficulties. Interestingly, there was high compliance from patients and caregivers to participate in the program.

Conclusions

With the limitation of low numbers of participants, our pilot program shows feasibility and efficacy of home-based rehabilitation program for LC patients. Patients’ high desire for the intervention emphasizes the unmet need. Further investigation and extended support after program completion is needed to maintain improvement.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Israeli Lung Cancer Foundation.

Funding

The Lung Ambition Alliance.

Disclosure

S. Shilo: Financial Interests, Personal and Institutional, Advisory Board: Roche, Sanofi. D. Urban: Financial Interests, Personal, Advisory Role: Roche, Merck, Jansen, BMS, Takeda, Medison. A. Zer: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Takeda, Pfizer, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, Steba, Oncohost; Financial Interests, Personal, Other, Safety Review Committee Member: Beyond Air; Financial Interests, Personal, Stocks/Shares: Nixio; Financial Interests, Institutional, Research Grant: BMS. A. Agbarya, N. Peled: Financial Interests, Personal, Advisory Role: Roche, AstraZeneca, BMS, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.